Other languages Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Delayed Nasdaq Other stock markets 15:49:24 2024-04-29 EDT			5-day change	1st Jan Change
2.505 ^USD	+3.51%		+13.86%	+95.70%

03-21	Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-21	Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21
Top Midday Gainers	03-12
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	03-12
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	03-12
Top Premarket Gainers	03-12
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	03-12
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	01-02
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Top Premarket Decliners	11-09
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	11-02
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-09-13
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-06-27
Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board	23-06-23
Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development	23-06-12
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-05-16
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Regulus Therapeutics Expects to Raise About $15 Million in Private Equity Placement; Shares Rise	23-04-13
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-04-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Other languages

Filters